Trust Co. of Vermont Acquires New Position in Pfizer Inc. $PFE

Trust Co. of Vermont acquired a new position in shares of Pfizer Inc. (NYSE:PFE) during the 2nd quarter, HoldingsChannel reports. The firm acquired 158,728 shares of the biopharmaceutical company’s stock, valued at approximately $3,822,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of PFE. Vermillion Wealth Management Inc. grew its holdings in shares of Pfizer by 19.4% during the first quarter. Vermillion Wealth Management Inc. now owns 2,352 shares of the biopharmaceutical company’s stock valued at $66,000 after purchasing an additional 382 shares during the last quarter. Eagle Capital Management LLC lifted its holdings in shares of Pfizer by 0.3% in the 1st quarter. Eagle Capital Management LLC now owns 126,573 shares of the biopharmaceutical company’s stock worth $3,554,000 after purchasing an additional 390 shares during the last quarter. Delta Financial Advisors LLC boosted its position in Pfizer by 1.6% during the 1st quarter. Delta Financial Advisors LLC now owns 25,266 shares of the biopharmaceutical company’s stock valued at $709,000 after purchasing an additional 398 shares during the period. Pines Wealth Management LLC boosted its position in Pfizer by 4.4% during the 4th quarter. Pines Wealth Management LLC now owns 9,430 shares of the biopharmaceutical company’s stock valued at $235,000 after purchasing an additional 400 shares during the period. Finally, Mount Vernon Associates Inc. MD grew its stake in Pfizer by 1.0% during the 1st quarter. Mount Vernon Associates Inc. MD now owns 41,919 shares of the biopharmaceutical company’s stock worth $1,177,000 after buying an additional 400 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer completed a Phase 1/2 study of PF-07868489, an experimental treatment for pulmonary arterial hypertension. The milestone supports early-stage pipeline progress, though additional clinical testing will be needed before any potential commercialization. Pfizer’s PF-07868489 PAH Study Reaches Completion
• Positive Sentiment: Several additional clinical updates highlighted progress across Pfizer’s development portfolio: completion of a Phase 1 atirmociclib study, completion of a drug-interaction study for PF-07248144, and a new Phase 1 liver study for atirmociclib. These milestones may reinforce confidence in Pfizer’s ability to replenish revenue as older products face competition. Atirmociclib Study Update PF-07248144 Study Update
• Positive Sentiment: Pfizer is also expanding real-world evidence efforts for prostate cancer therapies, Ibrance in advanced breast cancer, and a migraine treatment study in India. These studies could support broader use and strengthen commercial evidence for existing medicines. Pfizer Real-World Prostate Cancer Study
• Positive Sentiment: Investor-oriented coverage remains constructive, citing Pfizer’s roughly 19% year-to-date gain, attractive dividend yield, and reported hedge-fund buying. The stock’s move toward its 52-week high suggests improving sentiment. Hedge Funds Buying Pfizer
• Neutral Sentiment: Unusually large options activity may increase short-term trading interest, but it does not establish a clear fundamental direction for PFE. Pfizer Options Trading
• Negative Sentiment: Coverage of settlements involving thousands of Depo-Provera lawsuits raises concerns about potential legal costs and ongoing liability. Analysts also continue to weigh whether new drugs and acquisitions can offset revenue losses from expiring patents. Pfizer Legal Claims

Analyst Ratings Changes

PFE has been the topic of a number of recent research reports. JPMorgan Chase & Co. cut their target price on Pfizer from $30.00 to $28.00 and set a “neutral” rating on the stock in a research note on Wednesday, July 8th. Citigroup upped their price target on shares of Pfizer from $26.00 to $27.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 29th. Wall Street Zen raised shares of Pfizer from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. UBS Group reiterated a “neutral” rating and issued a $27.00 price objective on shares of Pfizer in a research report on Wednesday, May 27th. Finally, HSBC cut shares of Pfizer from a “buy” rating to a “hold” rating and decreased their target price for the stock from $32.00 to $28.00 in a research report on Monday, July 6th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, Pfizer has a consensus rating of “Hold” and an average price target of $28.28.

Pfizer Stock Up 0.8%

Shares of Pfizer stock opened at $28.00 on Friday. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96. Pfizer Inc. has a 1-year low of $23.58 and a 1-year high of $28.75. The business’s fifty day moving average price is $25.30 and its two-hundred day moving average price is $26.25. The company has a market capitalization of $159.59 billion, a P/E ratio of 36.84 and a beta of 0.34.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.68 by $0.09. The company had revenue of $15.03 billion during the quarter, compared to analysts’ expectations of $14.40 billion. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The company’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.78 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, research analysts forecast that Pfizer Inc. will post 2.98 EPS for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.1%. The ex-dividend date is Friday, July 24th. Pfizer’s dividend payout ratio is currently 226.32%.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.